眼科

• 论著 • 上一篇    下一篇

玻璃体内注射康柏西普治疗早产儿视网膜病变的6个月疗效观察

周真宝  杨晖  王娜  苏丽苗  卓楠
 
  

  1. 361006 厦门市儿童医院眼科(周真宝、杨晖、王娜、苏丽苗);361006厦门市中医院预防保健科(卓楠)
  • 收稿日期:2018-03-29 出版日期:2019-01-25 发布日期:2019-01-29
  • 通讯作者: 杨晖,Email:xmyh9808@126.com

Efficacy of six months on intravitreal injection of conbercept for retinopathy of prematurity

ZHOU Zhen-bao1, YANG Hui1, WANG Na1, SU Li-miao1, ZHUO Nan2.   

  1. 1. Department of Ophthalmology, Xiamen Children’s Hospital, Xiamen 361006, China; 2. Department of Healthy Protection, Traditional Chinese Medicine Hospital of Xiamen, Xiamen 361006, China
  • Received:2018-03-29 Online:2019-01-25 Published:2019-01-29
  • Contact: YANG Hui, Email: xmyh9808@126.com

摘要:

目的 观察玻璃体内注射康柏西普治疗早产儿视网膜病变(retinopathy of prematurity,ROP)的疗效。设计 回顾性病例系列。研究对象 2017年1-12月厦门市儿童医院ROP患儿24例(47眼),其中阈值病变或阈值前病变Ⅰ型33眼,急进型后极部ROP 14眼。方法 患眼玻璃体内单次注射康柏西普0.03 ml,术后1、2、4、6、10、14、18、24周进行眼底随访复查。治疗有效为附加病变消失或血管纡曲、扩张减轻,嵴淡化或消退,周边无血管区开始血管化。主要指标 治疗有效及复发的眼数。结果 行1次注射者39眼;行2次注射者4眼,联合视网膜激光光凝者4眼,行玻璃体切除术者1眼。所有患眼治疗均有效,随访期间未见复发者。随访期间,2眼于注射后1周见局部沿血管分布的白色渗出,余均未见与药物或治疗相关的眼局部及全身并发症。结论 玻璃体内注射康柏西普治疗ROP有效,但远期安全性尚待评估。(眼科, 2019, 28: 52-55)

关键词: 早产儿视网膜病变, 康柏西普

Abstract:

 Objective To evaluate the effectiveness of intravitreal injection of conbercept (IVC) for retinopathy of prematurity (ROP). Design Retrospective case series. Participants 24 patients (47 eyes) of ROP including threshold lesions or pre-threshold lesions of type I in 33 eyes and aggressive posterior ROP (AP-ROP) in 14 eyes had received IVC in Xiamen Children’s Hospital from January to December 2017. Methods All patients were treated with IVC 0.03 ml. Follow-up examinations were performed at 1, 2, 4, 6, 10, 14, 18, 24 weeks after treatment. Effective treatment included disappearance of additional lesions, reduction of vasodilation, crest regression and vascularization of peripheral non-vascularized areas. Main Outcome Measures Numbers of eyes with effectiveness or recurrence. Results All the eyes had received the IVC. 39 eyes were cured for single injection. 4 eyes had received twice injections. 4 eyes had required additional laser photocogulation. 1 eye had received vitrectomy. All the treatments were effective, and no recurrence was found in the follow-up examinations. During the follow-up, local punctiform effusion which was along with the retinal blood vessel was observed in 2 eyes following the first examination. No notable ocular and systemic complications related to the IVC injections were observed. Conclusions IVC is effective in the treatment of ROP, but the safety need to be evaluated for a long time. (Ophthalmol CHN, 2019, 28: 52-55)

Key words: retinopathy of prematurity, conbercept